Stockscreener 앱 받기
36.53
1.27%
-0.47
시간 외 거래:
36.28
-0.25
-0.68%
전일 마감가:
$37.00
열려 있는:
$36.5
하루 거래량:
1.86M
Relative Volume:
1.33
시가총액:
$3.84B
수익:
$628.56M
순이익/손실:
$141.82M
주가수익비율:
28.99
EPS:
1.26
순현금흐름:
$142.60M
1주 성능:
+4.97%
1개월 성능:
-55.98%
6개월 성능:
-46.41%
1년 성능:
-29.33%
1일 변동 폭
$36.13
$37.50
1주일 범위
$34.28
$38.44
52주 변동 폭
$32.99
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
36.53 | 3.89B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-31 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 개시 | UBS | Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Why Corcept Therapeutics Incorporated stock is a must watch in 2025 - ulpravda.ru
Is Corcept Therapeutics Incorporated stock in correction or buying zonePortfolio Update Summary & Fast Gaining Stock Reports - ulpravda.ru
Published on: 2026-01-08 22:12:30 - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics IncorporatedCORT - PR Newswire
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - Business Wire
Corcept Therapeutics Shares Plunge Over 50% Following FDA Complete Response Letter - Intellectia AI
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman - GlobeNewswire Inc.
Buybacks Report: Is Corcept Therapeutics Incorporated HTD stock among top earnings playsJuly 2025 Trade Ideas & Safe Swing Trade Setups - moha.gov.vn
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT) - TMX Newsfile
Fraud Investigation Opened: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) on Behalf of Shareholders - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept ... - Bluefield Daily Telegraph
Corcept Therapeutics Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50%Hagens Berman - Investing News Network
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - GlobeNewswire Inc.
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50%Hagens Berman - Finviz
Potential Securities Fraud: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) - ACCESS Newswire
CORT ACTIVE INVESTIGATION: Lost Money on Corcept Therapeutics Incorporated? Contact Levi & Korsinsky Now - ACCESS Newswire
CORCEPT THERAPEUTICS is Being Investigated for Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - NewMediaWire
Corcept Therapeutics Incorporated Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsCORT - ACCESS Newswire
Why Corcept (CORT) Stock Is Trading Lower Today - Finviz
Why Is Crinetics Pharma Stock Soaring Monday?Crinetics Pharmaceuticals (NASDAQ:CRNX) - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Shares Down 6.9% Following Analyst Downgrade - MarketBeat
Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? - Yahoo Finance
1 Healthcare Stock to Target This Week and 2 We Turn Down - Finviz
What is HC Wainwright's Estimate for CORT FY2030 Earnings? - MarketBeat
Why is CORT stock falling today? - MSN
Fraud Investigation: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) on Behalf of Shareholders - ACCESS Newswire
Why Is CORT Stock Falling Today? - Asianet Newsable
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law Violations - NewMediaWire
Synergy Asset Management LLC Raises Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Why Corcept Therapeutics plummeted by 50% today - MSN
Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) Over Potential Securities Fraud Allegations - ACCESS Newswire
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), FibroBiologics, Inc. (FBLG) and Corcept Therapeutics (CORT) - The Globe and Mail
Corcept Therapeutics (CORT) stock rebounds today after FDA setback — here’s what investors are watching next - ts2.tech
Corcept setback as relacorilant filing for hypercortisolism is rejected - The Pharma Letter
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism - Finviz
FDA rejects relacorilant for Cushing’s-related high blood pressure - Cushing's Disease News
Corcept Therapeutics (NASDAQ:CORT) Trading Up 9.7%Here's What Happened - MarketBeat
The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away - Barchart.com
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations - FinancialContent
Implied Volatility Surging for Corcept Stock Options - Yahoo Finance
Canaccord Genuity Adjusts Price Target for Corcept Therapeutics (CORT) | CORT Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Mind Medicine (MNMD) - The Globe and Mail
Ulta Beauty To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Given New $99.00 Price Target at Canaccord Genuity Group - MarketBeat
CORT ALERT: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated for Possible Securities Fraud Violations - ACCESS Newswire
Corcept Therapeutics stock price target lowered to $90 at H.C. Wainwright - Investing.com Canada
Corcept Therapeutics stock price target cut by Canaccord on FDA setback - Investing.com Canada
Corcept Therapeutics (CORT) Faces FDA Setback, But Growth Potent - GuruFocus
HC Wainwright & Co. Lowers Price Target for Corcept Therapeutics (CORT) | CORT Stock News - GuruFocus
FDA rejects drug for hormone disorder - medwatch.com
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.80%
4.56%
자본화:
|
볼륨(24시간):